Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Phase 2 Completed 32 enrolled Massachusetts General Hospital Dana-Farber Cancer Institute · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy followed by donor cord blood transplantation.

Timeline

Start: 2005-08
Primary completion: 2007-11
Completion: 2011-11

Publications

Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20;115(20):4111-9. doi: 10.1182/blood-2009-09-244145. Epub 2010 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	—	—
Subject	Tacrolimus	Small molecule	—	—
Background	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Protein / enzyme biologic	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous
Background	G-CSF	Unknown	—	—
Background	Melphalan	Small molecule	—	Intravenous

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Summary

Timeline

Publications

Drugs

Indications